OnabotulinumtoxinA  ||| S:0 E:19 ||| JJ
treatment  ||| S:19 E:29 ||| NN
of  ||| S:29 E:32 ||| IN
mild  ||| S:32 E:37 ||| JJ
glabellar  ||| S:37 E:47 ||| JJ
lines  ||| S:47 E:53 ||| NNS
in  ||| S:53 E:56 ||| IN
repose  ||| S:56 E:63 ||| JJ
OnabotulinumtoxinA  ||| S:63 E:82 ||| NN
is  ||| S:82 E:85 ||| VBZ
an  ||| S:85 E:88 ||| DT
established  ||| S:88 E:100 ||| JJ
treatment  ||| S:100 E:110 ||| NN
for  ||| S:110 E:114 ||| IN
glabellar  ||| S:114 E:124 ||| JJ
frown  ||| S:124 E:130 ||| JJ
lines ||| S:130 E:135 ||| NNS
,  ||| S:135 E:137 ||| ,
but  ||| S:137 E:141 ||| CC
its  ||| S:141 E:145 ||| PRP$
effects  ||| S:145 E:153 ||| NNS
on  ||| S:153 E:156 ||| IN
lines  ||| S:156 E:162 ||| NNS
at  ||| S:162 E:165 ||| IN
repose  ||| S:165 E:172 ||| NNS
are  ||| S:172 E:176 ||| VBP
less  ||| S:176 E:181 ||| RBR
well  ||| S:181 E:186 ||| RB
documented ||| S:186 E:196 ||| VBN
.  ||| S:196 E:198 ||| .
To  ||| S:198 E:201 ||| TO
assess  ||| S:201 E:208 ||| VB
the  ||| S:208 E:212 ||| DT
effect  ||| S:212 E:219 ||| NN
of  ||| S:219 E:222 ||| IN
onabotulinumtoxinA  ||| S:222 E:241 ||| JJ
on  ||| S:241 E:244 ||| IN
elimination  ||| S:244 E:256 ||| NN
of  ||| S:256 E:259 ||| IN
mild  ||| S:259 E:264 ||| JJ
lines  ||| S:264 E:270 ||| NNS
at  ||| S:270 E:273 ||| IN
repose ||| S:273 E:279 ||| NN
.  ||| S:279 E:281 ||| .
Data  ||| S:281 E:286 ||| NNS
from  ||| S:286 E:291 ||| IN
two  ||| S:291 E:295 ||| CD
randomized ||| S:295 E:305 ||| NN
,  ||| S:305 E:307 ||| ,
double-blind ||| S:307 E:319 ||| NNP
,  ||| S:319 E:321 ||| ,
placebo-controlled  ||| S:321 E:340 ||| JJ
studies  ||| S:340 E:348 ||| NNS
were  ||| S:348 E:353 ||| VBD
included ||| S:353 E:361 ||| VBN
.  ||| S:361 E:363 ||| .
Elimination  ||| S:363 E:375 ||| NN
of  ||| S:375 E:378 ||| IN
mild  ||| S:378 E:383 ||| JJ
lines  ||| S:383 E:389 ||| NNS
at  ||| S:389 E:392 ||| IN
repose  ||| S:392 E:399 ||| NN
was  ||| S:399 E:403 ||| VBD
defined  ||| S:403 E:411 ||| VBN
as  ||| S:411 E:414 ||| IN
change  ||| S:414 E:421 ||| NN
from  ||| S:421 E:426 ||| IN
mild  ||| S:426 E:431 ||| JJ
to  ||| S:431 E:434 ||| TO
none  ||| S:434 E:439 ||| NN
on  ||| S:439 E:442 ||| IN
the  ||| S:442 E:446 ||| DT
Facial  ||| S:446 E:453 ||| NNP
Wrinkle  ||| S:453 E:461 ||| NNP
Scale ||| S:461 E:466 ||| NNP
.  ||| S:466 E:468 ||| .
Analysis  ||| S:468 E:477 ||| NNP
included  ||| S:477 E:486 ||| VBD
183  ||| S:486 E:490 ||| CD
participants  ||| S:490 E:503 ||| NNS
who  ||| S:503 E:507 ||| WP
received  ||| S:507 E:516 ||| VBD
20  ||| S:516 E:519 ||| CD
U  ||| S:519 E:521 ||| NNP
of  ||| S:521 E:524 ||| IN
onabotulinumtoxinA  ||| S:524 E:543 ||| JJ
and  ||| S:543 E:547 ||| CC
64  ||| S:547 E:550 ||| CD
participants  ||| S:550 E:563 ||| NNS
who  ||| S:563 E:567 ||| WP
received  ||| S:567 E:576 ||| VBD
placebo ||| S:576 E:583 ||| CD
,  ||| S:583 E:585 ||| ,
all  ||| S:585 E:589 ||| DT
with  ||| S:589 E:594 ||| IN
mild  ||| S:594 E:599 ||| JJ
lines  ||| S:599 E:605 ||| NNS
at  ||| S:605 E:608 ||| IN
repose  ||| S:608 E:615 ||| NN
at  ||| S:615 E:618 ||| IN
baseline ||| S:618 E:626 ||| NN
.  ||| S:626 E:628 ||| .
Participants  ||| S:628 E:641 ||| NNS
were  ||| S:641 E:646 ||| VBD
evaluated  ||| S:646 E:656 ||| VBN
7 ||| S:656 E:657 ||| CD
,  ||| S:657 E:659 ||| ,
30 ||| S:659 E:661 ||| CD
,  ||| S:661 E:663 ||| ,
60 ||| S:663 E:665 ||| CD
,  ||| S:665 E:667 ||| ,
90 ||| S:667 E:669 ||| CD
,  ||| S:669 E:671 ||| ,
and  ||| S:671 E:675 ||| CC
120  ||| S:675 E:679 ||| CD
days  ||| S:679 E:684 ||| NNS
posttreatment ||| S:684 E:697 ||| VBD
.  ||| S:697 E:699 ||| .
Compared  ||| S:699 E:708 ||| VBN
to  ||| S:708 E:711 ||| TO
placebo ||| S:711 E:718 ||| VB
,  ||| S:718 E:720 ||| ,
onabotulinumtoxinA-treated  ||| S:720 E:747 ||| JJ
participants  ||| S:747 E:760 ||| NNS
were  ||| S:760 E:765 ||| VBD
significantly  ||| S:765 E:779 ||| RB
more  ||| S:779 E:784 ||| RBR
likely  ||| S:784 E:791 ||| JJ
to  ||| S:791 E:794 ||| TO
have  ||| S:794 E:799 ||| VB
their  ||| S:799 E:805 ||| PRP$
lines  ||| S:805 E:811 ||| NNS
at  ||| S:811 E:814 ||| IN
repose  ||| S:814 E:821 ||| VBG
eliminated  ||| S:821 E:832 ||| VBN
at  ||| S:832 E:835 ||| IN
each  ||| S:835 E:840 ||| DT
study  ||| S:840 E:846 ||| NN
day ||| S:846 E:849 ||| NN
;  ||| S:849 E:851 ||| :
[ ||| S:851 E:852 ||| -LRB-
odds  ||| S:852 E:857 ||| NNS
ratios  ||| S:857 E:864 ||| VBP
ranged  ||| S:864 E:871 ||| VBN
from  ||| S:871 E:876 ||| IN
42.7  ||| S:876 E:881 ||| CD
( ||| S:881 E:882 ||| -LRB-
95 ||| S:882 E:884 ||| CD
%  ||| S:884 E:886 ||| NN
confidence  ||| S:886 E:897 ||| NN
interval  ||| S:897 E:906 ||| NNS
( ||| S:906 E:907 ||| -LRB-
CI ||| S:907 E:909 ||| NNP
) ||| S:909 E:910 ||| -RRB-
=12.9-141.9 ||| S:910 E:921 ||| CD
)  ||| S:921 E:923 ||| -RRB-
at  ||| S:923 E:926 ||| IN
day  ||| S:926 E:930 ||| NN
30  ||| S:930 E:933 ||| CD
to  ||| S:933 E:936 ||| TO
4.9  ||| S:936 E:940 ||| CD
( ||| S:940 E:941 ||| -LRB-
95 ||| S:941 E:943 ||| CD
%  ||| S:943 E:945 ||| NN
CI=2.2-10.8 ||| S:945 E:956 ||| CD
)  ||| S:956 E:958 ||| -RRB-
at  ||| S:958 E:961 ||| IN
day  ||| S:961 E:965 ||| NN
120  ||| S:965 E:969 ||| CD
( ||| S:969 E:970 ||| -LRB-
p  ||| S:970 E:971 ||| JJ
< ||| S:971 E:972 ||| SYM
.0001  ||| S:972 E:978 ||| NN
at  ||| S:978 E:981 ||| IN
each  ||| S:981 E:986 ||| DT
day ||| S:986 E:989 ||| NN
) ||| S:989 E:990 ||| -RRB-
] ||| S:990 E:991 ||| -RRB-
.  ||| S:991 E:993 ||| .
The  ||| S:993 E:997 ||| DT
highest  ||| S:997 E:1005 ||| JJS
response  ||| S:1005 E:1014 ||| NN
rate  ||| S:1014 E:1019 ||| NN
was  ||| S:1019 E:1023 ||| VBD
observed  ||| S:1023 E:1032 ||| VBN
at  ||| S:1032 E:1035 ||| IN
day  ||| S:1035 E:1039 ||| NN
30  ||| S:1039 E:1042 ||| CD
( ||| S:1042 E:1043 ||| -LRB-
68 ||| S:1043 E:1045 ||| CD
% ||| S:1045 E:1046 ||| NN
) ||| S:1046 E:1047 ||| -RRB-
.  ||| S:1047 E:1049 ||| .
OnabotulinumtoxinA  ||| S:1049 E:1068 ||| NNP
has  ||| S:1068 E:1072 ||| VBZ
demonstrated  ||| S:1072 E:1085 ||| VBN
the  ||| S:1085 E:1089 ||| DT
ability  ||| S:1089 E:1097 ||| NN
to  ||| S:1097 E:1100 ||| TO
eliminate  ||| S:1100 E:1110 ||| VB
mild  ||| S:1110 E:1115 ||| JJ
glabellar  ||| S:1115 E:1125 ||| JJ
lines  ||| S:1125 E:1131 ||| NNS
at  ||| S:1131 E:1134 ||| IN
repose  ||| S:1134 E:1141 ||| NN
for  ||| S:1141 E:1145 ||| IN
a  ||| S:1145 E:1147 ||| DT
significant  ||| S:1147 E:1159 ||| JJ
number  ||| S:1159 E:1166 ||| NN
of  ||| S:1166 E:1169 ||| IN
patients ||| S:1169 E:1177 ||| NNS
.  ||| S:1177 E:1179 ||| .
This  ||| S:1179 E:1184 ||| DT
effect ||| S:1184 E:1190 ||| NN
,  ||| S:1190 E:1192 ||| ,
albeit  ||| S:1192 E:1199 ||| IN
more  ||| S:1199 E:1204 ||| JJR
subtle  ||| S:1204 E:1211 ||| NN
than  ||| S:1211 E:1216 ||| IN
the  ||| S:1216 E:1220 ||| DT
effect  ||| S:1220 E:1227 ||| NN
on  ||| S:1227 E:1230 ||| IN
dynamic  ||| S:1230 E:1238 ||| JJ
or  ||| S:1238 E:1241 ||| CC
more  ||| S:1241 E:1246 ||| RBR
severe  ||| S:1246 E:1253 ||| JJ
glabellar  ||| S:1253 E:1263 ||| JJ
lines ||| S:1263 E:1268 ||| NNS
,  ||| S:1268 E:1270 ||| ,
may  ||| S:1270 E:1274 ||| MD
be  ||| S:1274 E:1277 ||| VB
an  ||| S:1277 E:1280 ||| DT
important  ||| S:1280 E:1290 ||| JJ
treatment  ||| S:1290 E:1300 ||| NN
goal  ||| S:1300 E:1305 ||| NN
for  ||| S:1305 E:1309 ||| IN
patients  ||| S:1309 E:1318 ||| NNS
who  ||| S:1318 E:1322 ||| WP
seek  ||| S:1322 E:1327 ||| VBP
a  ||| S:1327 E:1329 ||| DT
smoother  ||| S:1329 E:1338 ||| JJ
appearance  ||| S:1338 E:1349 ||| NN
at  ||| S:1349 E:1352 ||| IN
repose ||| S:1352 E:1358 ||| NN
.  ||| S:1358 E:1360 ||| .
